These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6250307)

  • 1. [Experimental development of immunity to pertussis].
    Kuznetsov EA; Shirko GN
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Apr; (4):60-5. PubMed ID: 6250307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
    Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
    Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the route of immunization on the protection of mice infected intracerebrally with Bordetella pertussis.
    Standfast AF; Dolby JM
    J Hyg (Lond); 1972 Sep; 70(3):487-501. PubMed ID: 4341998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of surface antigens in the protective potency of Bordetella pertussis suspensions as measured by the intracerebral challenge technique in mice.
    Holt LB; Spasojevíc V
    J Med Microbiol; 1968 Aug; 1(1):119-26. PubMed ID: 4318938
    [No Abstract]   [Full Text] [Related]  

  • 5. Pitfalls in the preparation of monotypic agglutinating antisera for Bordetella pertussis.
    Holt LB
    J Med Microbiol; 1968 Nov; 1(2):169-80. PubMed ID: 4318535
    [No Abstract]   [Full Text] [Related]  

  • 6. [Protective effects of human gamma globulin preparations against experimental aerosol infections of mice with Bordetella pertussis].
    Imaizumi A; Suzuki Y; Sato Y
    Kansenshogaku Zasshi; 1984 Jun; 58(6):518-24. PubMed ID: 6092492
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunogenic value of the diphtheria-tetanus-pertussis trivaccine depending on the quantitative variations of its antigenic components. IV. Immunogenic properties of the pertussis compound].
    Andreescu V; Caffé I; Marion M; Pozsgi N; Stănică E; Stoian C; Kranzdorf H
    Arch Roum Pathol Exp Microbiol; 1970 Sep; 29(3):487-92. PubMed ID: 4328575
    [No Abstract]   [Full Text] [Related]  

  • 9. Serospecific protection of mice against intranasal infection with Bordetella pertussis.
    Robinson A; Gorringe AR; Funnell SG; Fernandez M
    Vaccine; 1989 Aug; 7(4):321-4. PubMed ID: 2573215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Physicochemical and biological characteristics of preparations of an antigenic complex isolated from the cultivation medium of Bordetella pertussis].
    Semina IE; Bazhanova IG; Tsvetkova NV; Remova TN; Ozeretskovskaia MN
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Aug; (8):76-9. PubMed ID: 2904201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenic properties of freshly isolated strains of the pertussis microbe].
    Shakirova RG; Kuznetsova LS; Kondrat'eva AM; Tsipkin VI; Korobova LM
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Mar; (3):10-4. PubMed ID: 2898847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunobiological properties of Bordetella pertussis lipopolysaccharide in the acellular pertussis vaccine].
    Zaĭtsev EM; Poddubikov AV; Britsina MV; Mertsalova NU; Ozeretskovskaia MN; Bazhanova IG; Plekhanova NG
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):20-4. PubMed ID: 24738289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Protective activity of whooping-cough convalescent serum and serum-IgA level in mice infected with Bordetella pertussis.
    Pittman M
    Lancet; 1976 Jul; 2(7977):156. PubMed ID: 59233
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunization with whole cell but not acellular pertussis vaccines primes CD4 T
    Wilk MM; Borkner L; Misiak A; Curham L; Allen AC; Mills KHG
    Emerg Microbes Infect; 2019; 8(1):169-185. PubMed ID: 30866771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the protective properties of anti-pertussis sera].
    Beilina VB
    Lab Delo; 1972; 7():432-4. PubMed ID: 4124731
    [No Abstract]   [Full Text] [Related]  

  • 16. [An acellular pertussis vaccine based on the natural complex of antigens isolated from the supernatant of a synthetic culture medium].
    Zakharova NS; Remova TN; Bazhanova IG; Ozeretskovskaia MH; Britsina MV; Shmeleva EI; Mertsalova NU; Ermolova EI; Sukhinova EE; Bulk VF; Sirotinskiĭ AV; Poluiianova AG; Sviridov VV; Vartanian IuP
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):67-70. PubMed ID: 9304334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
    Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
    Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
    Calver GA; Burton WW; Gardell CY
    Can J Microbiol; 1993 Aug; 39(8):759-66. PubMed ID: 8106134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of humoral, cellular and non-specific immunity on intracerebral Bordetella pertussis infections in mice.
    Dolby JM; Dolby DE; Bronne-Shanbury CJ
    J Hyg (Lond); 1975 Feb; 74(1):85-102. PubMed ID: 163275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitoxin in human pertussis immune globulins.
    Ferngren H; Granström M
    J Biol Stand; 1986 Oct; 14(4):297-303. PubMed ID: 2881931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.